Salute e Benessere

Waters Expands Alliance iS Bio HPLC Product Line with Photodiode Array Detector…

"The addition of the Alliance iS Bio HPLC System with PDA detection allows biopharmaceutical laboratories to perform enhanced spectral analysis, including impurity detection, peak purity analysis, multi-wavelength detection, and method validation, to deliver safe and effective products," said Fraser McLeod, Vice President, General Manager, QA/QC, at Waters Corporation. "Built on the Alliance iS HPLC Platform, the system is designed to simplify the analysis of complex…
PR Newswire
01/04/2025

Evaxion announces business update and full year 2024 financial results

COPENHAGEN, Denmark, April 1, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces full year 2024 financial results. Business highlights2024 and the first months of 2025 saw Evaxion make substantial progress in both business development, research and development and financing. Key highlights are listed below. Our transformational partnership with MSD...
Nasdaq GlobeNewswire
01/04/2025

Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive…

Company expands global footprint by establishing U.S. operation Company expands global footprint by establishing U.S. operation COPENHAGEN, Denmark , April 1, 2025 /PRNewswire/ -- Adcendo, a biotech company pioneering the development of first- and potential best-in-class antibody-drug conjugates (ADCs) for cancers with a high unmet medical need, today announced two important Board changes and a key addition to the executive leadership team.Laura Shawver, Ph.D. will join as Chair...
PR Newswire
01/04/2025

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680…

Vibrance-3 is a phase 2, randomized, double-blind, dose-range-finding, placebo-controlled study evaluating the safety and efficacy of ALKS 2680 in adults with IH. Participants will be randomized to receive one of three doses of ALKS 2680 (10 mg, 14 mg or 18 mg) or placebo to be taken once-daily for eight weeks. The primary endpoint will assess, by dose level, whether participants taking ALKS 2680 experience a greater decrease in sleepiness compared to participants taking placebo alone, as…
PR Newswire
01/04/2025

ESTEVE signs a licensing agreement for a severe primary insulin-like growth…

"As a rare disorder, patients suffering SPIGFD, often face difficulties associated with receiving a late correct diagnosis, with consequent delayed treatment initiation with limited access to appropriate therapy. This has a considerable impact on the physical health and quality of life of these patients.2 The disease awareness and the multidisciplinary approach are critical to improve those people's lives. This standard of care medicine is perfectly aligned with our strategy,focused on…
PR Newswire
01/04/2025

Sysmex's PA-100 AST System: Revolutionising UTI diagnosis and treatment with…

Sysmex's PA-100 AST System reduces the time for UTI diagnosis to 15 minutes and determines the optimal antibiotic within 30 minutes. A recently published budget impact analysis suggests potential healthcare savings based on modelled projections in Spain. Millions are suffering UTIs globallyUTIs are among the most common bacterial infections, affecting over 400 million people annually. Delays in diagnosis and reliance on empirical antibiotic treatments often lead to suboptimal outcomes,...
Nasdaq GlobeNewswire
01/04/2025

The European Commission refers lecanemab decision to Appeal Committee

If the marketing authorization application for lecanemab is approved, the approval will apply to all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway. Leqembi is already approved in the US, Japan, China, Great Britain and other markets. If the marketing authorization application for lecanemab is approved, the approval will apply to all 27 European Union member states, as well asIceland,Liechtenstein, andNorway. Leqembi is already approved in the US,Japan...
PR Newswire
01/04/2025

Revolutionizing Oral Care: Natch Launches Groundbreaking Postbiotic Dental Care…

Science Meets Innovation: Why Postbiotics are the Future of Dentistry Science Meets Innovation: Why Postbiotics are the Future of Dentistry Recent microbiome research confirms that a balanced oral flora is essential for long-term dental health. Natch integrates these latest scientific learnings into its new formulas by harnessing the power of postbiotics—bioactive compounds that can effectively help reduce inflammation and support the immune response in the oral cavity, helping to protect...
PR Newswire
01/04/2025

Smartee Accelerates Globalization with GS Technology in Spain

Prof. Gang Shen, Smartee's R&D Chief Scientist, was invited by the congress to make a keynote speech. His speech captivated audiences on Mandibular Forward Repositioning Therapy Correcting Severe Class II Jaw Discrepancy in Adults Caused by Mandibular Postural Retrusion. Combining 30 years of clinical research with actionable strategies, Prof. Shen demonstrated how Mandibular Repositioning Technology addresses challenges like mandibular retrusion. His session underscored Smartee's commitment…
PR Newswire
01/04/2025

Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the…

/ XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it will host an in-person and virtual R&D Day on Tuesday, April 15, 2025 from 10:00 AM to 12:00PM ET at the Intercontinental New York Barclay hotel. To register for the event,click here. The event will provide an update on Oculis' portfolio of innovative late-stage clinical...
Nasdaq GlobeNewswire
01/04/2025

SHL Medical opens new US$220 million manufacturing facility in the US to serve…

Strengthening production capacity and US market presence Strengthening production capacity and US market presence SHL Medical is significantly increasing its production capacity to meet growing demand inNorth Americawhile strengthening supply chain resilience. "US-based production is a major step forward in our global expansion and reinforces our position as the leader in providing end-to-end drug delivery solutions," saidUlrich Faessler, CEO & Chairman of SHL Medical. "With…
PR Newswire
01/04/2025

Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual…

Details of the poster presentations are as follows: Details of the poster presentations are as follows: Poster Title:Comprehensive Characterization of DT-7012, a Differentiated CCR8-Depleting Antibody for the Treatment of Solid TumorsSession Category:Experimental and Molecular TherapeuticsSession Title: Antireceptors and Other Biological Therapeutic AgentsDate and Time:Sunday 27 th April 2025, 14:00 –17:00 CDT Location:Poster Section 15Poster Board Number:4...
PR Newswire
01/04/2025

Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)

Right to participate and registration Right to participate and registration (A) Participation at the meeting venue A person who wishes to attend the meeting venue in person or by proxy must If the shareholder is represented by proxy, a written and dated power of attorney signed by the shareholder shall be issued for the proxy. Proxy forms are available at the company's websitewww.sobi.com. If the power of attorney has been issued by a legal entity, a registration certificate...
PR Newswire
01/04/2025

PeptiGrowth Inc. is Launching a Novel Synthetic Peptide: KGF alternative peptide…

About KGF alternative peptide (FGFR2b agonist) [Product code: PG-012] About KGF alternative peptide (FGFR2b agonist) [Product code: PG-012] PG-012, KGF alternative peptide, is a dimeric peptide composed of cyclic peptides designed to bind specifically to FGFR2b. Like KGF, PG-012 effectively interacts with FGFR2b and exhibits agonistic activity against FGFR2b (see diagram below). We conducted a comparative study on the functions of KGF alternative peptide (PG-012) and commercially...
PR Newswire
01/04/2025

Inside information: Change in the Fiskars Group Leadership Team - new CEO of…

"I am excited to welcome Daniel to our team as the new CEO of Vita. Daniel is a perfect fit to lead Vita, considering his extensive experience from CEO roles in world-class luxury and consumer brands, both in Europe and the United States. During the recent years and in line with our strategy, Vita has gone through a genuine transformation. We have carefully built foundations and I am convinced that Daniel will bring visionary leadership to Vita to tap into long-term growth…
PR Newswire
01/04/2025

Zelluna ASA [ZLNA]: Ex reverse share split today

Issuer name: Zelluna ASA Ex. date: 1 April 2025 Type of corporate action: Reverse share splitOther information: Reverse split ratio – ten (10) old shares give one (1) new share. New par value of NOK 1 per share New ISIN is NO 001 3524942.For further information, please contact:Hans Vassgård Eid, CFO, Zelluna ASA Email:[email protected]: +47 482 48632 About Zelluna ASAZelluna's mission is to deliver transformative treatments with the capacity to cure advanced solid...
Nasdaq GlobeNewswire
01/04/2025

ONWARD Medical Reports Full Year 2024 Financial and Operating Results and Shares…

Received FDA authorization and recorded first commercial sales of ARC-EX SystemSecured strategic investment from Ottobock and extended cash runway for two yearsGained exclusive rights to premier brain-computer interface technology EINDHOVEN, The Netherlands, April01, 2025(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with...
Nasdaq GlobeNewswire
01/04/2025

The Smoothest Beer Creates the Smoothest Skin Cream? Heineken® Silver Blurs…

Disrupting Expectations, One Smooth Move at a Time Disrupting Expectations, One Smooth Move at a Time Pushing category boundaries is in Heineken® Silver's DNA. Brewed at -1°C for a refreshingly crisp taste, the beer has always redefined smoothness. Now, in true Heineken® Silver fashion, the brand is making waves with its unconventional approach to brand engagement and sparking curiosity and conversation. What started as a joke was just too smooth not to make real. " The Heineken®...
PR Newswire
01/04/2025

Innocan Pharma Reports Full Year 2024 Results with Revenues more than Doubling…

Management Comments Management Comments Iris Bincovich, the CEO of Innocan commented:"We are delighted with our strong financial performance in 2024, concluding with outstanding year-end results. This achievement reflects our team's unwavering commitment to excellence, innovation, and strategic execution. We are focused on moving ahead aggressively on our two pathways, Human & Animal, with the LTP-CDB injection, our non-opioid Chronic Pain Management solution. "We remain...
PR Newswire
31/03/2025

Total number of shares and voting rights in Zealand Pharma as of March 31, 2025

Company announcement – No. 8 / 2025 Total number of shares and voting rights in Zealand Pharma as of March 31, 2025Copenhagen, Denmark, March 31, 2025– Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company…
Nasdaq GlobeNewswire
31/03/2025

Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox…

COPENHAGEN, Denmark, March 31, 2025– Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS ®(Smallpox and Mpox Vaccine, Live, Non-replicating) for prevention of smallpox and mpox disease in adults 18 years of age and older. This approval will provide additional flexibility for stockpiling against a smallpox event or mpox outbreak. The approval follows a standard review with the FDA of a...
Nasdaq GlobeNewswire
31/03/2025

Casino Group: Information regarding buy-out of minority shareholders of Cnova…

Information regarding buy-out of minority shareholdersof Cnova N.V. Paris, France / Amsterdam, the Netherlands, 31 March 2025 Casino, Guichard-Perrachon S.A. (Euronext Paris: CO; ISIN: FR001400OKR3) (" Casino ") announces as follows: as from 2 April 2025 and following the judgment rendered by the Enterprise Chamber of the Court of Appeal in Amsterdam, the Netherlands (the " Enterprise Chamber ") on 11 February 2025, the buy-out procedure of the minority shareholders of Cnova…
Nasdaq GlobeNewswire
31/03/2025

Hospital Beds Market to Reach $7.09 Billion by 2031, Growing at a CAGR of 6.4%…

Key Market Growth Drivers and Trends: Key Market Growth Drivers and Trends: The global hospital beds market is witnessing steady growth due to the increasing geriatric population, rising prevalence of chronic diseases, and growing demand for technologically advanced medical facilities. The expanding healthcare infrastructure, particularly in emerging economies, is also fueling market growth. According to the World Health Organization (WHO), the global population aged 60 years and older...
PR Newswire
31/03/2025

IBA – ACQUISITION OF OWN SHARES

Immediate Release – March 31 st, 2025 Louvain-la-Neuve, Belgium, March 31 st, 2025 -In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24 th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the...
Nasdaq GlobeNewswire
31/03/2025
Altri  Comunicati